Metabolon Target
Lipid Mediators of Inflammation Targeted Panel
Identify biomarkers
Support drug efficacy
Improve sensitivity
About Lipid Mediators
Lipid mediators are a class of bioactive lipids produced locally through specific biosynthetic pathways in response to extracellular stimuli. Lipid mediators are involved in many cellular processes, and their dysregulation has been linked to various conditions, including inflammation, which can be symptoms of underlying disease. Lipid mediators of inflammation are critical in generating and resolving inflammation, and their signature provides relevant information on patients’ inflammatory status and immune response.1
The metabolic consequences of inflammation may be widespread and lead to comorbidities, such as accelerated atherosclerosis, cardiovascular disease, or neuroinflammatory diseases. Metabolomic analysis targeting lipid mediators of inflammation may thus provide novel targets or biomarkers for therapeutic intervention in these major human diseases.
The Metabolon Lipid Mediators of Inflammation Targeted Panel detects 58 species across six metabolite classes, including pro-inflammatory mediators, anti-inflammatory mediators, prostaglandins, hydroxy/epoxy fatty acids-related mediators, endocannabinoids, and polyunsaturated fatty acids (PUFAs). Advance your research with absolute quantification of these metabolites that could lead to novel biomarker discovery. The Lipid Mediators of Inflammation Targeted Panel is positioned to complement our existing Global Discovery Panel and several other inflammation panels. With over 20 years of experience helping commercial and academic studies gain insights from metabolomic analyses and with over 3,000 citations in scientific journals, Metabolon is leading the way in applied metabolomics solutions worldwide.
Lipid Mediators of Inflammation Targeted Panel Details
Swipe left/right to view the full table.
| LLOQ* | |
|---|---|
| Metabolite | Plasma (ng/mL) |
| Pro-inflammatory Mediators | |
| LTB4 | 0.613 |
| LTD4 | 10 |
| LTE4 | 1.55 |
| LTC4† | 4.86 |
| TXB2 | 3.13 |
| Anti-inflammatory Mediators | |
| 15-LXA4 | 0.245 |
| LXA4 | 0.245 |
| LXA5 | 0.297 |
| LXB4 | 6.2 |
| Maresin 1 | 6.18 |
| Maresin 2 | 1.22 |
| MCTR3 | 2.46 |
| Protectin D1 | 2.48 |
| Protectin DX | 0.613 |
| PCTR1† | 6.13 |
| 17-RvD3 | 5.96 |
| RvD1 | 0.311 |
| RvD2 | 60.25 |
| RvD4 | 0.308 |
| RvD5 | 2.46 |
| RvE1 | 2.39 |
| RvE2 | 12.5 |
| Prostaglandins | |
| 13,14-dihydro-15-keto PGD2 | 6.13 |
| 13,14-dihydro-15-keto PGF2α | 3.13 |
| 15-keto PGF2α | 12.4 |
| 20-OH PGF2α | 6.13 |
| PGD2 | 12.5 |
| PGE2 | 6.25 |
| PGJ2 | 0.959 |
| Hydroxy/epoxy Fatty Acids-related Mediators | |
| 12-HHTrE | 49.2 |
| 5,6-DiHETE | 0.313 |
| 9,10-DiHOME | 12.5 |
| 5,6-DiHETrE† | 0.613 |
| 12,13-EpOME† | 26.7 |
| 13,14-EpDPA† | 6.25 |
| 17,18-EpETE† | 12.5 |
| 19,20-EpDPA† | 17.4 |
| 5,6-EET† | 435 |
| 8,9-EET† | 25 |
| 12-HEPE | 0.618 |
| 12-HETE | 1.92 |
| 13-HODE | 5 |
| 13-HOTrE | 2.5 |
| 16-HDHA | 6.25 |
| 17-HDHA | 6.16 |
| 20-HETE | 0.625 |
| 5-HEPE | 1.25 |
| 9-HETE | 3.68 |
| 9-HODE | 4.92 |
| 9-HOTrE | 2.49 |
| 5-HETE† | 3.42 |
| Endocannabinoids | |
| Anandamide (AEA) | 2.49 |
| Docosahexaenoyl-EA (DHEA) | 1.76 |
| PUFAs | |
| Arachidonic acid (AA)† | 500 |
| Docosahexaenoic acid (DHA)† | 97.8 |
| Docosapentaenoic acid (DPA)† | 98.9 |
| Eicosapentaenoic acid (EPA)† | 123 |
*Lower Limit of Quantitation (LLOQ) varies for each sample type.
†Note that these analytes did not meet the full validation criteria but do meet validation criteria sufficiently to support biological insights derived from their measurements.
Analysis Method and Instrumentation:
LC-MS/MS (Agilent 1290 UHPLC/Sciex QTrap 7500)
| Sample Type and Required Amounts | |
|---|---|
| Sample Type | Sample Requirements |
| Plasma | 150 to 200 µL |
Others on request
Disclaimer: This method is for Research Use Only and is not to be used for diagnostic purposes.
Delivering Absolute Quantification for Research and Biomarker Analysis
Our readily available or custom developed quantitative assays help you achieve your research and biomarker validation objectives with precise and fully validated methods. Our targeted assays and panels cover >1,000 metabolites and lipids across a wide range of biochemical classes, metabolic pathways, and physiological processes, and they can be customized to best fit any application.
Lipid Mediators of Inflammation Targeted Panel Applications
Inflammation
The importance of inflammation in the development of multiple diseases- and health-related conditions including neurodegeneration, diabetes, cardiovascular disease, cancer, and inflammatory bowel disease is undisputed. Metabolomics can inform on inflammatory processes by providing a readout of the small molecules of an organism, tissue, biofluid, etc. This allows for direct molecular phenotyping of inflammation beyond the standard protein markers of typical assays. Metabolon offers several targeted assays, including oxysterols, fatty acids, kynurenine/tryptophan, and a range of others (central carbon, glucose tolerance, branched-chain amino acids, β-hydroxybutyrate) that can also inform on overall cardiovascular health that is often linked with inflammatory processes.
Cardiovascular Diseases
Heart disease is a leading cause of death worldwide, and there are numerous factors that lead to this and other cardiovascular diseases (CVD). Metabolomics can illuminate cardiovascular disease at multiple levels. In preclinical studies, such as with cardiomyocytes or heart tissue from model organisms, understanding mitochondrial function, energetics, and redox status can drive critical insights into disease mechanisms. In human studies, metabolomics offers the opportunity to account for well-established CVD risk factors such as cholesterol and complex lipids, while simultaneously profiling thousands of other biochemicals in an unbiased fashion to enable the discovery of novel disease mechanisms and biomarkers.
Neuroscience
It is well-established that a low-carbohydrate, high-fat ketogenic diet (KD) can help treat refractory epilepsy, which affects more than a third of epileptic patients who don’t respond to existing anticonvulsive drugs. What scientists haven’t understood until recently is how this kind of diet translates to brain activity. The answer for this aspect of epilepsy lies in the gut microbiome. There are many other neurological disorders like Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease and more. While so much remains to be understood about brain science, we do know that metabolomics is uniquely poised to understand the brain because of the ability of metabolites, small molecules, to cross the blood-brain barrier providing unique insights.
Big Insights with Metabolon
Cited in over 3,000 publications, we help scientists and manufacturers gain greater insight into their studies through metabolomics. See how our approach can become a successful part of your workflow.
Related Metabolomics Resources
Contact Us
Talk with an expert
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.
Corporate Headquarters
617 Davis Drive, Suite 100
Morrisville, NC 27560
Mailing Address:
P.O. Box 110407
Research Triangle Park, NC 27709
+1 (919) 572-1711
International Headquarters
Metabolon GmbH
Zeppelinstraße 3
85399 Hallbergmoos
Germany
References
1. Cioccari L, Luethi N, Masoodi M. Lipid Mediators in Critically Ill Patients: A Step Towards Precision Medicine. Front Immunol. 2020;11:599853. doi:10.3389/fimmu.2020.599853
